MaxCyte, Inc. Research & Development Agreement with NIAID (2054H)
June 06 2017 - 1:01AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 2054H
MaxCyte, Inc.
06 June 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Cooperative Research and Development Agreement
MaxCyte and National Institute of Allergy and Infectious
Diseases to
Collaborate on Research for Ultra-Rare Disease Therapy
- Researchers to explore development of new therapies for
X-linked chronic granulomatous disease (CGD) using MaxCyte's
gene-correction platform
Maryland, USA - 06 June 2017 - MaxCyte, Inc. (LSE: MXCT, MXCR)
today announces it has entered into a Cooperative Research and
Development Agreement ("CRADA") with the National Institutes of
Health's ("NIH") National Institute of Allergy and Infectious
Diseases ("NIAID") to develop treatments for X-linked chronic
granulomatous disease ("CGD") using next-generation gene correction
leveraging CRISPR/Cas9 and MaxCyte's Flow Electroporation(TM)
Platform.
CGD is an inherited genetic disorder that impairs the function
of the immune system and leads to ongoing and severe bacterial
infections. The disease affects approximately 1 in 250,000* people
worldwide and is currently only treatable through high-risk
treatments, such as allogeneic bone marrow transplantation.
NIAID will conduct pre-clinical research evaluating the
effectiveness and safety of CRISPR-Cas9 gene editing on models of
CGD by "correcting" the faulty gene that causes the disease.
MaxCyte will supply mRNA molecules and focus on leveraging its Flow
Electroporation(TM) Platform to develop robust and scalable
processes that result in a clinically meaningful correction of
mutated gene sequences.
Doug Doerfler, President & CEO of MaxCyte, said: "We are
delighted to continue our collaboration with NIAID, one of the
world's leading infectious disease institutes, which is leveraging
MaxCyte's expertise in developing a new generation of genome
editing therapy for CGD patients. We believe that this work will
validate the use of our platform for developing gene-editing
therapies via rapid, cost-effective manufacturing. This agreement,
along with recent data announced from a research effort between
MaxCyte and NHLBI of NIH in sickle cell disease, further
demonstrates our commitment to deliver new therapies to patients
where there is an extremely high unmet medical need."
The MaxCyte/NIAID CRADA marks the latest step in the
collaboration between the Company and the NIAID to advance new
treatments for CGD, and reflects MaxCyte platform's ability to be
used in multiple fields of indication. MaxCyte received Maryland
Stem Cell Research Fund grants in 2015 and 2017 to pursue its
collaboration with the NIAID to develop preclinical processes and
clinical-scale protocols for CGD and other rare diseases. MaxCyte
also presented data generated in the collaboration at the 2015
American Society of Gene and Cell Therapy (ASGCT) annual meeting on
the ability of genome editing in hematopoietic stem cells to
restore oxidase activity. Earlier this year, MaxCyte shared data
from the collaboration at the ASGCT's annual meeting highlighting
the achievement of therapeutic levels of gene correction in
hematopoietic stem cells obtained from CGD patients.
References:
*MedScape
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated
to driving the acceleration of the discovery, development,
manufacturing and commercialization of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face
significant challenges. For more information, visit http://www.maxcyte.com/
###
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Madhusudan V. Peshwa, PhD,
Chief Scientific Officer,
Executive Vice President,
Cellular Therapies
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRDGGDLGSGBGRU
(END) Dow Jones Newswires
June 06, 2017 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024